FOLH1 and prostate carcinoma: The funding of PSMA PET imaging in Australia was supported by prospective clinical trials demonstrating management impact,17diagnostic performance and safety,7and economic benefit.18As discussed, in theranostics, the TheraP trial has contributed to approvals of [177Lu]Lu-PSMA internationally, with the results of ENZAp and UpfrontPSMA likely to further add to the treatment landscape in prostate cancer.